Jennifer Patnaik
Concepts (431)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 32 | 2026 | 497 | 5.700 |
Why?
| | Macular Degeneration | 17 | 2026 | 196 | 4.470 |
Why?
| | Cataract | 18 | 2024 | 238 | 3.780 |
Why?
| | Geographic Atrophy | 12 | 2025 | 103 | 3.460 |
Why?
| | Wet Macular Degeneration | 8 | 2026 | 63 | 2.980 |
Why?
| | Phacoemulsification | 14 | 2025 | 123 | 2.520 |
Why?
| | Registries | 10 | 2025 | 2382 | 2.050 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 211 | 2.030 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 49 | 1.810 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 277 | 1.740 |
Why?
| | Fluorescein Angiography | 10 | 2026 | 195 | 1.680 |
Why?
| | Ophthalmology | 7 | 2026 | 121 | 1.620 |
Why?
| | Intraocular Pressure | 12 | 2026 | 332 | 1.580 |
Why?
| | Cataract Extraction | 11 | 2026 | 120 | 1.570 |
Why?
| | Follow-Up Studies | 27 | 2026 | 5397 | 1.180 |
Why?
| | Optometrists | 3 | 2026 | 11 | 1.160 |
Why?
| | Glaucoma | 8 | 2025 | 253 | 1.130 |
Why?
| | Optometry | 2 | 2025 | 8 | 1.100 |
Why?
| | Retinopathy of Prematurity | 4 | 2026 | 183 | 1.090 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.070 |
Why?
| | Aged, 80 and over | 30 | 2026 | 8351 | 0.980 |
Why?
| | Retinal Detachment | 6 | 2023 | 74 | 0.950 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 0.930 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.920 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.910 |
Why?
| | Retrospective Studies | 57 | 2026 | 17291 | 0.910 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 6 | 0.910 |
Why?
| | Myopia | 7 | 2024 | 59 | 0.900 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.890 |
Why?
| | Aged | 52 | 2026 | 26251 | 0.860 |
Why?
| | Humans | 126 | 2026 | 145625 | 0.810 |
Why?
| | Surveys and Questionnaires | 16 | 2026 | 6050 | 0.800 |
Why?
| | Burnout, Professional | 3 | 2025 | 489 | 0.780 |
Why?
| | Refraction, Ocular | 6 | 2024 | 47 | 0.760 |
Why?
| | Female | 79 | 2026 | 79080 | 0.720 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.720 |
Why?
| | Intraoperative Complications | 6 | 2024 | 154 | 0.710 |
Why?
| | Presbyopia | 1 | 2022 | 14 | 0.690 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.690 |
Why?
| | Eye Diseases | 2 | 2020 | 98 | 0.690 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.680 |
Why?
| | Uveitis | 4 | 2025 | 151 | 0.680 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.680 |
Why?
| | Trabeculectomy | 5 | 2025 | 75 | 0.670 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.670 |
Why?
| | Male | 72 | 2026 | 73014 | 0.670 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.660 |
Why?
| | Automobile Driving | 2 | 2022 | 156 | 0.630 |
Why?
| | Colorado | 22 | 2026 | 4588 | 0.620 |
Why?
| | Middle Aged | 41 | 2026 | 36359 | 0.620 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 105 | 0.610 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.600 |
Why?
| | Laser Therapy | 1 | 2021 | 146 | 0.590 |
Why?
| | Dementia | 1 | 2023 | 322 | 0.580 |
Why?
| | Vitrectomy | 6 | 2025 | 74 | 0.570 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 144 | 0.560 |
Why?
| | Postoperative Complications | 7 | 2026 | 2962 | 0.560 |
Why?
| | Lens, Crystalline | 1 | 2020 | 136 | 0.550 |
Why?
| | Lasers, Excimer | 3 | 2024 | 30 | 0.530 |
Why?
| | Metformin | 1 | 2021 | 328 | 0.520 |
Why?
| | Angiogenesis Inhibitors | 3 | 2026 | 238 | 0.520 |
Why?
| | Strabismus | 3 | 2023 | 71 | 0.510 |
Why?
| | Complement Activation | 5 | 2025 | 412 | 0.500 |
Why?
| | West Nile Fever | 3 | 2011 | 57 | 0.500 |
Why?
| | Internal Medicine | 1 | 2019 | 279 | 0.480 |
Why?
| | Laser Coagulation | 3 | 2026 | 80 | 0.480 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5875 | 0.470 |
Why?
| | Emergency Medicine | 1 | 2019 | 278 | 0.470 |
Why?
| | Refractive Errors | 3 | 2025 | 36 | 0.470 |
Why?
| | Choroid | 3 | 2025 | 80 | 0.460 |
Why?
| | Complement System Proteins | 4 | 2025 | 324 | 0.460 |
Why?
| | Prevalence | 7 | 2025 | 2852 | 0.450 |
Why?
| | Family Practice | 1 | 2019 | 422 | 0.450 |
Why?
| | Self Report | 2 | 2022 | 869 | 0.440 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2026 | 543 | 0.410 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2411 | 0.410 |
Why?
| | United States | 19 | 2026 | 16041 | 0.410 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 80 | 0.400 |
Why?
| | Cornea | 3 | 2025 | 156 | 0.400 |
Why?
| | Sickness Impact Profile | 2 | 2026 | 67 | 0.400 |
Why?
| | Biomarkers | 9 | 2025 | 4329 | 0.400 |
Why?
| | Internet | 4 | 2023 | 656 | 0.400 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.390 |
Why?
| | Multimodal Imaging | 2 | 2025 | 138 | 0.390 |
Why?
| | Glucocorticoids | 4 | 2026 | 536 | 0.390 |
Why?
| | Commerce | 2 | 2013 | 80 | 0.380 |
Why?
| | Vitreous Body | 4 | 2022 | 118 | 0.380 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1101 | 0.380 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 14 | 0.370 |
Why?
| | Smoking Prevention | 1 | 2013 | 168 | 0.360 |
Why?
| | Tobacco Products | 1 | 2013 | 90 | 0.350 |
Why?
| | Risk Factors | 14 | 2025 | 10840 | 0.350 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 91 | 0.350 |
Why?
| | Macula Lutea | 2 | 2023 | 21 | 0.350 |
Why?
| | Disease Progression | 5 | 2026 | 2857 | 0.340 |
Why?
| | Fundus Oculi | 3 | 2025 | 89 | 0.330 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.330 |
Why?
| | Retinal Diseases | 2 | 2023 | 101 | 0.330 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 13 | 0.330 |
Why?
| | Telemedicine | 3 | 2026 | 956 | 0.320 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Quality of Life | 6 | 2026 | 3187 | 0.310 |
Why?
| | Ophthalmologists | 2 | 2026 | 21 | 0.300 |
Why?
| | Comorbidity | 2 | 2011 | 1652 | 0.290 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.290 |
Why?
| | Treatment Outcome | 12 | 2026 | 11744 | 0.290 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 104 | 0.290 |
Why?
| | Artificial Intelligence | 2 | 2024 | 385 | 0.290 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1318 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2623 | 0.280 |
Why?
| | Tertiary Care Centers | 2 | 2026 | 194 | 0.270 |
Why?
| | Infant | 13 | 2026 | 10093 | 0.260 |
Why?
| | Hepatitis A | 2 | 2011 | 25 | 0.260 |
Why?
| | Bangladesh | 3 | 2022 | 64 | 0.260 |
Why?
| | West Nile virus | 1 | 2007 | 41 | 0.260 |
Why?
| | Healthcare Disparities | 2 | 2025 | 728 | 0.250 |
Why?
| | Gestational Age | 4 | 2026 | 989 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7079 | 0.250 |
Why?
| | Adult | 24 | 2026 | 40821 | 0.250 |
Why?
| | Local Government | 1 | 2006 | 27 | 0.240 |
Why?
| | Health Promotion | 1 | 2013 | 786 | 0.240 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.240 |
Why?
| | Restaurants | 1 | 2006 | 25 | 0.240 |
Why?
| | Prospective Studies | 7 | 2025 | 8087 | 0.230 |
Why?
| | Chronic Disease | 2 | 2011 | 1824 | 0.230 |
Why?
| | Blepharitis | 1 | 2026 | 8 | 0.230 |
Why?
| | Vision Disorders | 3 | 2022 | 178 | 0.230 |
Why?
| | Keratoconjunctivitis | 1 | 2026 | 11 | 0.230 |
Why?
| | Mass Screening | 2 | 2024 | 1300 | 0.230 |
Why?
| | Public Health Administration | 1 | 2006 | 69 | 0.230 |
Why?
| | Scleritis | 2 | 2025 | 28 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2026 | 40 | 0.230 |
Why?
| | Blindness | 1 | 2026 | 51 | 0.230 |
Why?
| | Eye Proteins | 1 | 2026 | 93 | 0.230 |
Why?
| | Visual Fields | 1 | 2026 | 116 | 0.220 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.220 |
Why?
| | Dry Eye Syndromes | 1 | 2026 | 56 | 0.220 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.220 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.220 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.220 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.210 |
Why?
| | Withholding Treatment | 1 | 2025 | 77 | 0.210 |
Why?
| | Occupational Stress | 1 | 2025 | 46 | 0.210 |
Why?
| | Surgery, Plastic | 1 | 2025 | 53 | 0.210 |
Why?
| | Birth Weight | 3 | 2022 | 521 | 0.210 |
Why?
| | Education, Distance | 1 | 2025 | 59 | 0.210 |
Why?
| | Retinoblastoma | 1 | 2024 | 53 | 0.210 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Child | 14 | 2026 | 22638 | 0.200 |
Why?
| | Optics and Photonics | 2 | 2021 | 38 | 0.200 |
Why?
| | Young Adult | 7 | 2026 | 14240 | 0.200 |
Why?
| | Adolescent | 12 | 2026 | 22451 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 49 | 0.190 |
Why?
| | Postoperative Period | 5 | 2025 | 344 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2024 | 1125 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Job Satisfaction | 1 | 2025 | 235 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 364 | 0.180 |
Why?
| | Endoscopy | 1 | 2025 | 316 | 0.180 |
Why?
| | Homosexuality, Male | 2 | 2020 | 231 | 0.180 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.180 |
Why?
| | Cohort Studies | 6 | 2022 | 6045 | 0.180 |
Why?
| | Eyelid Diseases | 1 | 2022 | 26 | 0.180 |
Why?
| | Compartment Syndromes | 1 | 2022 | 36 | 0.180 |
Why?
| | Odds Ratio | 4 | 2019 | 1070 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 21 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.180 |
Why?
| | Eyeglasses | 1 | 2022 | 26 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2910 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 23 | 0.180 |
Why?
| | Infant, Newborn | 6 | 2026 | 6449 | 0.170 |
Why?
| | Patient Satisfaction | 2 | 2024 | 698 | 0.170 |
Why?
| | Ocular Hypertension | 1 | 2022 | 71 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.160 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.160 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.160 |
Why?
| | Neonatal Screening | 1 | 2022 | 185 | 0.160 |
Why?
| | Perception | 2 | 2021 | 372 | 0.160 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 47 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Child, Preschool | 10 | 2026 | 11888 | 0.160 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 84 | 0.160 |
Why?
| | Accidents, Traffic | 1 | 2022 | 192 | 0.160 |
Why?
| | SEER Program | 2 | 2011 | 233 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1101 | 0.150 |
Why?
| | Scleral Buckling | 1 | 2019 | 16 | 0.150 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 147 | 0.150 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 21 | 0.150 |
Why?
| | Language | 1 | 2023 | 313 | 0.150 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 15 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 250 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2020 | 72 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 321 | 0.150 |
Why?
| | Protective Factors | 1 | 2019 | 97 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 49 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 70 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 86 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 136 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3678 | 0.140 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.140 |
Why?
| | Accreditation | 1 | 2019 | 100 | 0.140 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2218 | 0.140 |
Why?
| | Refugees | 1 | 2020 | 83 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 57 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 119 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 529 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3633 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 120 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.130 |
Why?
| | Infant, Premature | 1 | 2022 | 622 | 0.130 |
Why?
| | Curriculum | 1 | 2025 | 1074 | 0.130 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1212 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 283 | 0.130 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 74 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 230 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 163 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2026 | 1370 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2020 | 248 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 218 | 0.120 |
Why?
| | Logistic Models | 2 | 2019 | 2112 | 0.110 |
Why?
| | Clinical Competence | 2 | 2025 | 1261 | 0.110 |
Why?
| | Population Surveillance | 2 | 2011 | 477 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 649 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 721 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1983 | 0.110 |
Why?
| | Inflammation | 3 | 2023 | 2915 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 566 | 0.100 |
Why?
| | Disease Outbreaks | 2 | 2008 | 420 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 81 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 99 | 0.100 |
Why?
| | Intravitreal Injections | 2 | 2026 | 73 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 954 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 764 | 0.090 |
Why?
| | Sexual Behavior | 4 | 2004 | 489 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 805 | 0.090 |
Why?
| | Medicare | 2 | 2024 | 907 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1411 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 244 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2011 | 178 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 8 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 222 | 0.070 |
Why?
| | Food Microbiology | 1 | 2009 | 39 | 0.070 |
Why?
| | Sex Factors | 2 | 2025 | 2101 | 0.070 |
Why?
| | Cause of Death | 1 | 2011 | 455 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 959 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 375 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1269 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2218 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 473 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 560 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 27 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 8 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 33 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 48 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 63 | 0.060 |
Why?
| | Health Services Administration | 1 | 2007 | 9 | 0.060 |
Why?
| | Chickens | 1 | 2007 | 169 | 0.060 |
Why?
| | Relief Work | 1 | 2007 | 18 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 845 | 0.060 |
Why?
| | Telephone | 1 | 2008 | 175 | 0.060 |
Why?
| | Geography | 1 | 2007 | 186 | 0.060 |
Why?
| | Birds | 1 | 2007 | 87 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 538 | 0.060 |
Why?
| | Horses | 1 | 2007 | 229 | 0.060 |
Why?
| | Ethiopia | 1 | 2026 | 43 | 0.060 |
Why?
| | Visual Field Tests | 1 | 2026 | 32 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1478 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3930 | 0.060 |
Why?
| | Environment | 1 | 2007 | 295 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 101 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 162 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2097 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 194 | 0.060 |
Why?
| | Bevacizumab | 1 | 2026 | 167 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1481 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 43 | 0.050 |
Why?
| | Adalimumab | 1 | 2025 | 53 | 0.050 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.050 |
Why?
| | Tomography | 1 | 2025 | 44 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.050 |
Why?
| | Ontario | 1 | 2024 | 91 | 0.050 |
Why?
| | Infliximab | 1 | 2025 | 107 | 0.050 |
Why?
| | Benchmarking | 1 | 2026 | 192 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 117 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 30 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 35 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 47 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 419 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 82 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 403 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 61 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 991 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 234 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 22 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 926 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 133 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 511 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 217 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 292 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 63 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 215 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1208 | 0.040 |
Why?
| | Orbit | 1 | 2022 | 67 | 0.040 |
Why?
| | Aqueous Humor | 1 | 2022 | 41 | 0.040 |
Why?
| | Global Health | 1 | 2025 | 402 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2023 | 494 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3186 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2026 | 561 | 0.040 |
Why?
| | Nicotine | 1 | 2005 | 334 | 0.040 |
Why?
| | Drug Implants | 1 | 2022 | 83 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 176 | 0.040 |
Why?
| | Capsulorhexis | 1 | 2021 | 9 | 0.040 |
Why?
| | Communication Barriers | 1 | 2023 | 129 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 119 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 132 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 317 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 181 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 123 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 236 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 68 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 440 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 66 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 321 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 824 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 7 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 90 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 483 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 91 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 346 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2078 | 0.040 |
Why?
| | HIV | 1 | 2020 | 249 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 452 | 0.040 |
Why?
| | Canada | 1 | 2020 | 430 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 39 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 427 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 253 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 10 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1878 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 124 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 150 | 0.030 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2023 | 514 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1062 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 574 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 627 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2910 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 777 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 236 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 357 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 632 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3005 | 0.030 |
Why?
| | Stents | 1 | 2021 | 551 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 267 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 942 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 519 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 798 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 878 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 771 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 896 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3396 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1531 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 945 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1118 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1021 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 545 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1935 | 0.020 |
Why?
| | Proteomics | 1 | 2020 | 1202 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2007 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 982 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1566 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1700 | 0.020 |
Why?
| | Animals | 3 | 2009 | 38030 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2357 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4331 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 59 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 45 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 140 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 142 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1996 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 15 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 22 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 385 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 151 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 94 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 134 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 202 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1992 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 172 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 585 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 67 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 153 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 68 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1033 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 93 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 39 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 867 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 278 | 0.010 |
Why?
| | Risk | 1 | 2004 | 917 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 771 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 496 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 3210 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|